STA Pharmaceutical, a WuXi AppTec company, will launch the new center at its integrated API process R&D and manufacturing site in Changzhou, China.
According to the company, the facility will allow it to perform rapid screening of metal catalysts, ligands, bases, acids, chemical resolving reagents, and amide formation coupling reagents.
Additionally, the technology uses a parallel interactive testing approach, the company said.
STA is currently training a team of scientists specialized in the technology who will move to the Changzhou site when the center becomes fully operational in November.